石药创新(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300765 石药创新

已收盘 08-27 15:00:00

{"stockData":{"symbol":"300765","market":"SZ","secType":"STK","nameCN":"石药创新","latestPrice":46.95,"timestamp":1787814189000,"preClose":45.5,"halted":0,"volume":37047228,"delay":0,"changeRate":0.0319,"floatShares":1405000000,"shares":1405000000,"eps":0.7282,"marketStatus":"已收盘","change":1.45,"latestTime":"08-27 15:00:00","open":45.66,"high":48.32,"low":43.9,"amount":1689000000,"amplitude":0.0971,"askPrice":46.96,"askSize":211,"bidPrice":46.95,"bidSize":132,"shortable":0,"etf":0,"ttmEps":0.7282,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787880600000},"marketStatusCode":5,"adr":0,"adjPreClose":45.5,"symbolType":"stock","openAndCloseTimeList":[[1787794200000,1787801400000],[1787806800000,1787814000000]],"highLimit":50.05,"lowLimit":40.95,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1404592944,"isCdr":false,"pbRate":16.23,"roa":"--","peRate":64.474046,"roe":"38.2%","epsLYR":-0.1731,"committee":0.184808,"marketValue":65946000000,"turnoverRate":0.0264,"status":0,"floatMarketCap":65946000000},"requestUrl":"/m/hq/s/300765","defaultTab":"news","newsList":[{"id":"2662879146","title":"石药创新最新公告：控股子公司药物获美国FDA快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2662879146","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662879146?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:17","pubTimestamp":1787735872,"startTime":"0","endTime":"0","summary":"石药创新(300765.SZ)公告称，公司控股子公司巨石生物研发的首创PD-1/IL-15双特异性融合蛋白SYS6090(JMT108)获美国FDA授予快速通道资格，用于治疗既往经标准系统性治疗后出现疾病进展的微卫星稳定或错配修复功能完整型转移性结直肠癌患者。该资格有助于加快药物开发与审批进程，但最终获批上市仍存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600038205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661224335","title":"8月24日石药创新跌7.67%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661224335","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661224335?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:41","pubTimestamp":1787560882,"startTime":"0","endTime":"0","summary":"证券之星消息，8月24日石药创新跌7.67%，收盘报45.24元，换手率3.35%，成交量47.05万手，成交额21.55亿元。重仓石药创新的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共29家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400022137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660027674","title":"8月20日石药创新涨20.00%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660027674","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660027674?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:43","pubTimestamp":1787215426,"startTime":"0","endTime":"0","summary":"证券之星消息，8月20日石药创新涨20.00%创60日新高，收盘报51.78元，换手率4.59%，成交量64.52万手，成交额32.28亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共29家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000029030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660436514","title":"石药创新(300765.SZ)控股子公司SYS6090启动Ib/II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2660436514","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660436514?lang=zh_cn&edition=full","pubTime":"2026-08-19 15:59","pubTimestamp":1787126378,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药创新 发布公告，公司控股子公司石药集团巨石生物制药有限公司已于近日启动一项评价SYS6090注射液联合治疗在肝细胞癌参与者中的安全性、耐受性及有效性的Ib/Ⅱ期临床试验。目前，SYS6090-007研究的参与者招募和筛选工作正在积极推进中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481899.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","IBBJ","MDTX","BMED","IBBQ","300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660499531","title":"股市必读：石药创新新发布《2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660499531","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660499531?lang=zh_cn&edition=full","pubTime":"2026-08-19 00:55","pubTimestamp":1787072112,"startTime":"0","endTime":"0","summary":"公司公告汇总：2026年半年度报告显示营业收入同比增长208.72%，归母净利润由上年同期亏损274.61万元转为盈利12.61亿元。第七届董事会第四次会议决议公告2026年8月14日召开第七届董事会第四次会议，审议通过《2026年半年度报告》及其摘要、《2026年半年度募集资金存放、管理与实际使用情况的专项报告》、增加2026年度日常关联交易预计额度、增加自有资金进行现金管理额度等议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900001080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660466660","title":"石药创新：截至2026年8月10日股东数为31,534户","url":"https://stock-news.laohu8.com/highlight/detail?id=2660466660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660466660?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:51","pubTimestamp":1787046673,"startTime":"0","endTime":"0","summary":"证券之星消息，石药创新(300765)08月18日在投资者关系平台上答复投资者关心的问题。投资者提问：您好！请问截至8月10日公司股东人数是多少，谢谢石药创新回复：您好，感谢您对公司的关注，截至2026年8月10日，公司合并普通账户和融资融券信用账户股东数为31,534户，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800031885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660090486","title":"图解石药创新中报：第二季度单季净利润同比增长5509.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660090486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660090486?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:43","pubTimestamp":1786959815,"startTime":"0","endTime":"0","summary":"证券之星消息，石药创新2026年中报显示，上半年度公司主营收入32.4亿元，同比上升208.72%；归母净利润12.61亿元，同比上升46025.71%；扣非净利润12.26亿元，同比上升3079.6%；其中2026年第二季度，公司单季度主营收入25.76亿元，同比上升345.92%；单季度归母净利润13.55亿元，同比上升5509.67%；单季度扣非净利润13.37亿元，同比上升12823.6%；负债率49.96%，投资收益-19.33万元，财务费用5305.31万元，毛利率76.74%。财报数据概要请见下图:本文数据来源于石药创新2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700023527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660486783","title":"石药创新(300765)7月20日股东户数2.54万户，较上期增加4.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660486783","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660486783?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:38","pubTimestamp":1786959517,"startTime":"0","endTime":"0","summary":"证券之星消息，近日石药创新披露，截至2026年7月20日公司股东户数为2.54万户，较7月10日增加1168.0户，增幅为4.81%。在化学制药行业个股中，石药创新股东户数低于行业平均水平，截至7月20日，化学制药行业平均股东户数为3.62万户。从股价来看，2026年7月10日至2026年7月20日，石药创新区间涨幅为7.55%，在此期间股东户数增加1168.0户，增幅为4.81%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700023359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118834795","title":"石药创新上半年净利润达13亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118834795","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118834795?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:50","pubTimestamp":1786956627,"startTime":"0","endTime":"0","summary":"路透社8月17日消息——石药创新制药股份有限公司（CSPC Innovation Pharmaceutical Co., Ltd.，股票代码：300765.SZ）公布上半年业绩。数据显示，公司净利润达到13亿元人民币（约合1.9294亿美元）。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0067412154.USD","LU1993786604.SGD","BK1521","01093","IE0008368742.USD","300765","LU1152091168.USD","LU1226287529.USD","LU1951186391.HKD","LU0072913022.USD","IE00B031HY20.USD","LU1807302812.USD","LU1813983027.USD","IE00BZ08YS42.EUR","LU0880133367.SGD","IE00BZ08YT58.USD","LU1328277881.USD","LU0315179316.USD","LU1226287792.SGD","LU1226288170.HKD","LU1960683339.HKD","LU1226288253.USD","BK1515","IE00B5MMRT66.SGD","LU0326950275.SGD","HK0000165453.HKD","LU1008478684.HKD","LU2039709279.SGD","IE0008369823.USD","SG9999004220.SGD","LU0501845795.SGD","BK0226","LU0314109678.HKD","KURE","LU1226287875.USD","IE00B543WZ88.USD","BK1191","LU0140636845.USD","LU1152091754.HKD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660485300","title":"石药创新(300765.SZ)发布上半年业绩，扭亏为盈至12.61亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660485300","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660485300?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:46","pubTimestamp":1786956378,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药创新 发布2026年半年度报告，报告期内，公司实现营业收入32.4亿元，同比增长208.72%。实现归属于上市公司股东的净利润12.61亿元。2026年一季度，公司顺利达成与Corbus合作项目II期临床启动里程碑，上半年已收取1,000万美元里程碑款项。2026年7月1日，公司再度与阿斯利康签署小干扰核酸创新药物全球合作协议，巨石生物有权收取3,000万美元首付款，项目后续里程碑合计最高可达174,000万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药创新(300765.SZ)发布上半年业绩，扭亏为盈至12.61亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660623485","title":"8月17日石药创新涨9.00%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660623485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660623485?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:44","pubTimestamp":1786956284,"startTime":"0","endTime":"0","summary":"证券之星消息，8月17日石药创新涨9.00%创60日新高，收盘报44.44元，换手率2.68%，成交量37.61万手，成交额16.61亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共29家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700021245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","159891","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658769979","title":"石药创新(300765.SZ)：巨石生物已收到阿斯利康支付的3000万美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2658769979","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658769979?lang=zh_cn&edition=full","pubTime":"2026-08-12 18:52","pubTimestamp":1786531939,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药创新(300765.SZ)发布公告，2026年7月1日，公司控股子公司巨石生物与阿斯利康签署《合作、选择权及授权协议》，将与阿斯利康在新型小干扰核酸候选药物领域开展战略合作，开发新型肝外递送小干扰分子核酸候选药物。根据协议约定，巨石生物已于2026年8月12日收到阿斯利康支付的3000万美元首付款(实际到账金额须扣除银行手续费)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","AZNH","LU2456880835.USD","LU1267930573.SGD","LU2462157665.USD","LU0310800379.SGD","LU0432979614.USD","LU2236285917.USD","LU0128525929.USD","300765","LU2089984988.USD","LU2237443382.USD","LU2237443895.HKD","LU0109394709.USD","LU0058720904.USD","LU2237443465.HKD","LU2237443549.SGD","BK0226","LU0889565916.HKD","LU2468319806.SGD","LU0708994859.HKD","LU0320765992.SGD","BK4568","LU0289739699.SGD","BK4585","LU0029864427.USD","LU2237443622.USD","LU2417539215.USD","IE00B3T34201.USD","LU1829250122.USD","BK4007","LU2237443978.SGD","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658963996","title":"8月11日石药创新现1007.39万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2658963996","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658963996?lang=zh_cn&edition=full","pubTime":"2026-08-11 17:25","pubTimestamp":1786440352,"startTime":"0","endTime":"0","summary":"证券之星消息，8月11日石药创新发生大宗交易，交易数据如下：近三个月该股共发生8笔大宗交易，合计成交2.16万手，折价成交2笔。该股近期无解禁股上市。截至2026年8月11日收盘，石药创新(300765)报收于43.31元，上涨6.2%，换手率2.36%，成交量33.17万手，成交额13.91亿元。该股最近90天内共有1家机构给出评级，买入评级1家。本文数据来源于深圳证券交易所大宗交易信息披露，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100027648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658986670","title":"石药创新(300765.SZ)子公司SYS6037注射液(猴痘mRNA疫苗)获得美国药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2658986670","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658986670?lang=zh_cn&edition=full","pubTime":"2026-08-10 15:49","pubTimestamp":1786348188,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药创新 发布公告，公司的控股子公司石药集团巨石生物制药有限公司于近日收到美国食品药品监督管理局通知，巨石生物和中国科学院微生物研究所合作开发的SYS6037注射液药品临床试验申请已获得美国FDA批准，可以在美国开展临床试验。SYS6037注射液为一款由单条mRNA链编码的多抗原猴痘疫苗，用于猴痘的预防。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300765","MRNX","IBBJ","BMED","MDTX","BK0226","MRNY","PSYK","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658986546","title":"石药创新：控股子公司猴痘mRNA疫苗获美国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2658986546","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658986546?lang=zh_cn&edition=full","pubTime":"2026-08-10 15:46","pubTimestamp":1786348007,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657568178","title":"股市必读：石药创新（300765）8月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2657568178","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657568178?lang=zh_cn&edition=full","pubTime":"2026-08-05 01:13","pubTimestamp":1785863602,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，石药创新报收于37.36元，上涨2.86%，换手率0.96%，成交量13.48万手，成交额5.05亿元。董秘最新回复投资者： 您好，创新药板块整体表现低迷，如果公司在这时候能够有回购计划，将会提振中小股东的持股信心！希望能够向董事会反馈董秘： 您好，感谢您的关注与建议，我们会将您的意见转达，谢谢。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500001523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656539047","title":"石药创新：公司生产经营活动一切正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2656539047","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656539047?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:27","pubTimestamp":1785835632,"startTime":"0","endTime":"0","summary":"证券之星消息，石药创新(300765)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，请问公司股价持续下跌是否已经触及异动披露标准？对比同行业明显公司股价下行更多。请问公司是否经营正常？是否有利空消息没有对投资者进行公布？石药创新回复：您好！公司生产经营活动一切正常，不存在应披露而未披露事项。公司将持续做好经营管理工作，努力提升内在价值。感谢您的关注与支持！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400028995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656027321","title":"石药创新(300765.SZ)子公司SYS6090启动Ib/II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2656027321","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656027321?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:33","pubTimestamp":1785746028,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药创新 发布公告，公司的控股子公司石药集团巨石生物制药有限公司已于近日启动一项评价SYS6090注射液联合治疗在晚期或转移性结直肠癌参与者中的安全性、耐受性及有效性的Ib/Ⅱ期临床试验。未来，公司将基于该研究的结果，继续推进SYS6090注射液联合治疗在结直肠癌参与者中的Ⅲ期确证性临床研究，进一步验证SYS6090注射液联合治疗方案的临床价值。目前，SYS6090-008研究的参与者招募与筛选工作正在积极推进中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300765","IBBJ","MDTX","IBBQ","BK0226","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655351077","title":"石药创新：公司将依据合同条款和企业会计准则对阿斯利康首付款进行会计处理","url":"https://stock-news.laohu8.com/highlight/detail?id=2655351077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655351077?lang=zh_cn&edition=full","pubTime":"2026-07-31 17:24","pubTimestamp":1785489866,"startTime":"0","endTime":"0","summary":"证券之星消息，石药创新(300765)07月31日在投资者关系平台上答复投资者关心的问题。投资者提问：公司已公告收到阿斯利康授权协议首付款4.2亿美元，这4.2亿美元上半年不确认收益吗？如果确认收益则公司净利润应该同比大幅增长，但到现在也没看到公司的预增公告，请问这4.2亿美元不能确认收入吗？石药创新回复：您好，感谢您对公司的关注，2026年半年度业绩预告已于2026年7月27日披露，公司将依据合同条款和企业会计准则对阿斯利康首付款进行会计处理，谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100028935.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655351788","title":"石药创新：公司2026年半年度业绩预告已于2026年7月27日披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2655351788","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655351788?lang=zh_cn&edition=full","pubTime":"2026-07-31 17:21","pubTimestamp":1785489670,"startTime":"0","endTime":"0","summary":"证券之星消息，石药创新(300765)07月31日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司是否发布中报业绩预告？石药创新回复：您好，感谢您对公司的关注，公司2026年半年度业绩预告已于2026年7月27日披露，谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100028837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787843238090,"stockEarnings":[{"period":"1week","weight":0.0545},{"period":"1month","weight":0.2493},{"period":"3month","weight":0.7473},{"period":"6month","weight":0.3775},{"period":"1year","weight":-0.1503},{"period":"ytd","weight":0.2614}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.0141},{"period":"3month","weight":-0.0454},{"period":"6month","weight":-0.0601},{"period":"1year","weight":0.0114},{"period":"ytd","weight":-0.0142}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"石药创新制药股份有限公司","boardCode":"AI0014","boardName":"食品制造业","stockholders":"31534人(较上一季度增加31.88%)","perCapita":"44542股","listingDate":"2019-03-22","address":"河北省石家庄市栾城区张举路62号","registeredCapital":"140459万元","survey":"　　石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是抗体药物、ADC药物、mRNA疫苗、药品、咖啡因、阿卡波糖、无水葡萄糖原料及果维康维生素C含片、维生素B族含片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一，已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。","listedPrice":24.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药创新(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药创新(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药创新,300765,石药创新股票,石药创新股票老虎,石药创新股票老虎国际,石药创新行情,石药创新股票行情,石药创新股价,石药创新股市,石药创新股票价格,石药创新股票交易,石药创新股票购买,石药创新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药创新(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药创新(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}